会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明申请
    • LIQUID CRYSTAL DISPLAY DEVICE
    • 液晶显示装置
    • US20140028937A1
    • 2014-01-30
    • US14009754
    • 2012-04-13
    • Seiichi Uchida
    • Seiichi Uchida
    • G02F1/1343
    • G02F1/134363G02F1/136213G02F2001/134318G02F2001/134345G09G3/3655G09G2300/0426G09G2300/0447G09G2300/0452G09G2300/0465G09G2300/0876G09G2320/028
    • A liquid crystal display device of the present invention is provided with: an array substrate (10) in which a pixel electrode (41), a TFT (20), and a storage capacitor element (30) are provided for each pixel (P); an opposite substrate (50) in which a plurality of common electrodes (59A, 59B) are provided for each pixel (P); a liquid crystal layer (81); and a driver circuit (4) that dividedly drives the liquid crystal layer (81) of each pixel (P) through each of the common electrodes (59A, 59B) by supplying a predetermined potential to each pixel electrode (41) and supplying different potentials to the respective common electrodes (59A, 59B) in each pixel (P). The liquid crystal display device according to the present invention has improved viewing angle dependency of the gamma characteristics, while increasing the aperture ratio of each pixel.
    • 本发明的液晶显示装置具备:为每个像素(P)提供像素电极(41),TFT(20)和存储电容元件(30)的阵列基板(10) ; 对于每个像素(P)提供多个公共电极(59A,59B)的相对基板(50)。 液晶层(81); 以及驱动电路(4),通过向每个像素电极(41)供给规定的电位,并且向不同的像素电极(41)供给不同的电位,通过各公共电极(59A,59B)分别驱动各像素(P)的液晶层 到各像素(P)中的公共电极(59A,59B)。 根据本发明的液晶显示装置在增加每个像素的开口率的同时具有改善的伽马特性的视角依赖性。
    • 34. 发明授权
    • N-substituted imidazol derivative
    • N-取代咪唑衍生物
    • US5965743A
    • 1999-10-12
    • US732232
    • 1997-03-03
    • Nobuo MochizukiSeiichi UchidaIzumi KumitaHiroyuki MiyamotoHiromi Ichihara
    • Nobuo MochizukiSeiichi UchidaIzumi KumitaHiroyuki MiyamotoHiromi Ichihara
    • C07D233/58C07D233/60C07D233/61C07D521/00A61K31/415
    • C07D231/12C07D233/56C07D249/08
    • The present invention is to provide novel imidazole derivatives effectual as an antihyperlipemic agent and therapeutic and preventive drugs for arteriosclerosis, and to provide methods for manufacturing the said derivatives.More particularly, the present invention is directed to the compounds represented by the following general formula [I]; ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, n is 0 or 1, X is N-r.sup.1 wherein r.sup.1 is hydrogen or lower alkyl, O, S, SO, SO.sub.2, CH.sub.2, CH(CH.sub.3), CONH or C(r.sup.2).dbd.NO wherein r.sup.2 is hydrogen or lower alkyl, m is 0 or an integer of from 1 to 12, and A is methyl or a group represented by the following general formula; ##STR2## wherein Y is N-r.sup.3 wherein r.sup.3 is hydrogen or lower alkyl, N(r.sup.4)SO.sub.2 wherein r.sup.4 is hydrogen or lower alkyl, O, S, SO, SO.sub.2, CH.sub.2, CH(CH.sub.3), CONH or C(r.sup.5).dbd.NO wherein r.sup.5 is hydrogen or lower alkyl, R.sup.2 is a halogen, a lower alkyl, a lower alkoxy, a cycloalkyl or COOr.sup.6 wherein r.sup.6 is hydrogen or a lower alkyl, and l is 0, 1, 2 or 3, however, m denotes an integer of from 6 to 9 when A is methyl, or m denotes 0 or an integer of from 1 to 6 when A is a group represented by the following general formula; ##STR3## and X and Y are each independently CH.sub.2 when m is 0, the pharmaceutically-acceptable salts thereof and methods for manufacturing the said compounds and the pharmaceutically-acceptable salts thereof.
    • PCT No.PCT / JP95 / 00827 Sec。 371日期1997年3月3日 102(e)1997年3月3日PCT PCT 1996年4月26日PCT公布。 WO95 / 29163 PCT出版物 日期:1995年11月2日本发明提供作为抗高血脂药物的新型咪唑衍生物和用于动脉硬化的治疗和预防药物,并提供制备所述衍生物的方法。 更具体地,本发明涉及由以下通式[I]表示的化合物。 其中R1是氢或低级烷基,n是0或1,X是N-r1,其中r1是氢或低级烷基,O,S,SO,SO2,CH2,CH(CH3),CONH或C(r2)= NO 其中,R 2为氢或低级烷基,m为0或1〜12的整数,A为甲基或下述通式所示的基团。 其中Y是N-r3,其中r3是氢或低级烷基,N(r4)SO2,其中r4是氢或低级烷基,O,S,SO,SO2,CH2,CH(CH3),CONH或C(r5)= NO 其中r5是氢或低级烷基,R2是卤素,低级烷基,低级烷氧基,环烷基或COOr6,其中r6是氢或低级烷基,l是0,1,2或3,然而,m表示 当A为甲基时,6〜9的整数,或者A为下述通式所示的基团时,m表示0或1〜6的整数。 并且当m为0时,X和Y各自独立地为CH 2,其药学上可接受的盐以及所述化合物及其药学上可接受的盐的制备方法。
    • 36. 发明授权
    • Liquid crystal display device
    • 液晶显示装置
    • US09229284B2
    • 2016-01-05
    • US14009754
    • 2012-04-13
    • Seiichi Uchida
    • Seiichi Uchida
    • G09G3/36G02F1/1343G02F1/1362
    • G02F1/134363G02F1/136213G02F2001/134318G02F2001/134345G09G3/3655G09G2300/0426G09G2300/0447G09G2300/0452G09G2300/0465G09G2300/0876G09G2320/028
    • A liquid crystal display device of the present invention is provided with: an array substrate (10) in which a pixel electrode (41), a TFT (20), and a storage capacitor element (30) are provided for each pixel (P); an opposite substrate (50) in which a plurality of common electrodes (59A, 59B) are provided for each pixel (P); a liquid crystal layer (81); and a driver circuit (4) that dividedly drives the liquid crystal layer (81) of each pixel (P) through each of the common electrodes (59A, 59B) by supplying a predetermined potential to each pixel electrode (41) and supplying different potentials to the respective common electrodes (59A, 59B) in each pixel (P). The liquid crystal display device according to the present invention has improved viewing angle dependency of the gamma characteristics, while increasing the aperture ratio of each pixel.
    • 本发明的液晶显示装置具备:为每个像素(P)提供像素电极(41),TFT(20)和存储电容元件(30)的阵列基板(10) ; 对于每个像素(P)提供多个公共电极(59A,59B)的相对基板(50)。 液晶层(81); 以及驱动电路(4),通过向每个像素电极(41)供给规定的电位,并且向不同的像素电极(41)供给不同的电位,通过各公共电极(59A,59B)分别驱动各像素(P)的液晶层 到各像素(P)中的公共电极(59A,59B)。 根据本发明的液晶显示装置在增加每个像素的开口率的同时具有改善的伽马特性的视角依赖性。
    • 39. 发明授权
    • Optically active compound
    • 光学活性化合物
    • US5856480A
    • 1999-01-05
    • US817872
    • 1997-05-01
    • Nobuo MochizukiNobuhiro UmedaSeiichi Uchida
    • Nobuo MochizukiNobuhiro UmedaSeiichi Uchida
    • C07D237/04A61K31/50
    • C07D237/04
    • The present invention is directed to (R)-(-)-4,5-dihydro-5-methyl-6-�4-�(2-propyl-3-oxo-1-cyclohexenyl)amino!phenyl!-3(2H)-pyridazinone, the crystalline form thereof and a method for manufacturing the said compound and the said crystalline form.The compound of the present invention has excellent inhibitory effect on platelet aggregation while giving less side effect, and therefore, it is useful to utilize the compound as an antithrombotic drug. In addition, the compound of the present invention has bronchodialatic effect as well, and it is therefore useful to utilize the compound for chemotherapy of chronic obstructive lung disease, such as asthma and bronchitis.Moreover, the compound of the present invention is useful for chemotherapy of the diseases relating to the concentration of cAMP in cells, such as hypertension, ulcer, diabetes mellitus and cancer.Again, crystalline form of the said compound is the most suitable form in order to supply stable and homogeneous bulk thereof.
    • PCT No.PCT / JP95 / 02295 371日期1997年5月1日 102(e)日期1997年5月1日PCT提交1995年11月10日PCT公布。 公开号WO96 / 15117 日期1996年5月23日本发明涉及(R) - ( - ) - 4,5-二氢-5-甲基-6- [4 - [(2-丙基-3-氧代-1-环己烯基)氨基]苯基 ] -3(2H) - 哒嗪酮,其结晶形式和制备所述化合物和所述结晶形式的方法。 本发明的化合物对于血小板聚集具有优异的抑制作用,同时具有较小的副作用,因此可用于该化合物作为抗血栓形成药物。 此外,本发明的化合物也具有支气管扩张作用,因此可用于化合物用于慢性阻塞性肺疾病如哮喘和支气管炎的化疗。 此外,本发明的化合物可用于与高血压,溃疡,糖尿病和癌症等细胞中cAMP浓度相关的疾病的化疗。 此外,所述化合物的结晶形式是最合适的形式,以便提供其稳定和均匀的体积。